Director Gary Pace Sells 119,323 Shares of Pacira BioSciences Inc (PCRX) [Yahoo! Finance]
Pacira BioSciences, Inc. (PCRX)
Last pacira biosciences, inc. earnings: 2/20 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.pacira.com
Company Research
Source: Yahoo! Finance
Director Gary Pace sold 119,323 shares of the company on March 8, 2024, according to a recent SEC filing. Gary Pace has been active in the market over the past year, selling a total of 124,338 shares and making no purchases of the company's stock. This latest transaction continues the trend observed in the insider transaction history for Pacira BioSciences Inc, which has seen 23 insider sells and no insider buys over the past year. On the day of the insider's recent sale, shares of Pacira BioSciences Inc were trading at $30.64, giving the company a market capitalization of $1.460 billion. The price-earnings ratio of the stock stands at 37.84, which is above the industry median of 22.945 but below the company's historical median price-earnings ratio. Considering the stock's price of $30.64 and the GuruFocus Value of $61.30, Pacira BioSciences Inc has a price-to-GF-Value ratio of 0.5, indicating that the stock is significantly undervalued according to GuruFocus's intrinsic value est
Show less
Read more
Impact Snapshot
Event Time:
PCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCRX alerts
High impacting Pacira BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
PCRX
News
- Pacira BioSciences (NASDAQ:PCRX) stock falls 4.1% in past week as three-year earnings and shareholder returns continue downward trend [Yahoo! Finance]Yahoo! Finance
- Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $45.00 price target on the stock.MarketBeat
- Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag [Yahoo! Finance]Yahoo! Finance
- Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee [Yahoo! Finance]Yahoo! Finance
PCRX
Earnings
- 2/29/24 - Beat
PCRX
Sec Filings
- 4/22/24 - Form ARS
- 4/22/24 - Form DEF
- 4/22/24 - Form DEFA14A
- PCRX's page on the SEC website